Clinical trial
ZD6474 Phase IIa Dose Finding Multicentre Study
NCT00252746 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00252746 |
|---|---|
| Title | ZD6474 Phase IIa Dose Finding Multicentre Study |
| Official title | A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated] |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | ZD6474 (vandetanib) 100mg, ZD6474 (vandetanib) 200mg, ZD6474 (vandetanib) 300mg |
| Enrollment | 53 |
| Start date | Dec 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Nov 15, 2005 |
| Last update posted | Aug 25, 2016 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: